Morning Briefing
Summaries of health policy coverage from major news organizations
Deal Between GSK, Brazil To Strengthen Country's Pharmaceutical R&D
GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company's vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
